Genflow Biosciences Share Discussion Threads

[cyberbub] 26/4/2024 15:27

Well as you suggest, just look at what happened last year when they announced a collaboration with Rochester, trebled in a couple of days :-)No advice intended of course.

[moneymunch] 26/4/2024 15:01

A very nice 650k buy just in at 1.9p!!! Gla :-)

[northeast14] 26/4/2024 14:46

Yes year end was this time last year. Thought they might release early again.

[moneymunch] 26/4/2024 14:34

News on patents, progress on pipeline, US investors, collaborators etc at anytime, but we're still awaiting Final reports from the 4 invivo studies to be officially published, which could be highly significant, although not sure if they're already in the mix as we progress to human clinical trials, or if there's going to be a peer-review or similar scientific publication, but Vera's podcast is well worth a listen as she goes into great depth of the studies they're carrying out on Sirt6, and interestingly enough, Vera hasn't published any news at all from her lab, so far this year???.Gla :-)


September 2023



The Company is conducting in-vivo evaluations of its centenarian SIRT6 gene therapy in four different NASH mice models in conjunction with four leading partners in the field: The University of Liverpool, UK, The University of Rochester, US, the International Clinical Research Center (FNUSA-ICRC) , Czech Republic and Physiogenex, France.

These studies have been wide reaching and have included the analysation of over 700 mice, with the intention of understanding the efficacy and safety of the Company's drug candidate in animal models with NASH and has generated essential information in preparation for clinical trials in humans. Final reports are expected by the end of 2023.

........

A fascinating and insightful Podcast interview with Vera Gorbunova from 24/10/23 discussing the promising potential for Sirt6 and how she is conducting indepth research in collaboration with Biotech companies, and confirms results should be available in a few months. Gla :-)

SIRT6 The Science Behind The Longevity Gene | Professor Vera Gorbunova Ep1

Oct. 24, 2023

[cyberbub] 26/4/2024 14:13

Northeast, GENF have until 30 June to release their final results (ie 6 months after the end of their financial year). They did release them in late April last year though. IMO the strength over the last couple of days might be something else eg the US patent?

[moneymunch] 26/4/2024 13:24

Not long now before sub 2p will be a distant memory with any luck, a major re-rate or two highly likely with plenty of significant positive newsflow stacking UP!!! Gla :-)

[moneymunch] 26/4/2024 11:27

Looking good and strong, very low free float with the majority of shares held tightly for greater things to come and so any good news should see a solid and significant re-rate. Gla holders, Momentum building, Genflow is all set for a stellar year ahead imho. ;-)

[northeast14] 25/4/2024 22:00

Nice one! I’m sure you won’t be disappointed

[prashaprash] 25/4/2024 21:42

Got 1.2 millions shares recently

[northeast14] 25/4/2024 21:22

I’m sure all this will come before end of play Tuesday when I think they need to RNS the year end by. I’m sure Eric will have something up his sleeve as he never disappoints

[cyberbub] 25/4/2024 16:16

The results are likely to make mediocre reading financially of course. The important thing will be a corporate and clinical update... Plus confirmation of cash reserves/runway...

[moneymunch] 25/4/2024 12:54

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,585 followers

23m

🧬 Genflow Biosciences has an updated presentation! 🧬

To learn more about the cutting-edge #biotech research & studies currently underway, as well as Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s strong investment thesis, click here:

#SIRT6 #GENF #NASH #aging #healthspan

[moneymunch] 25/4/2024 07:19

Let's hope so Northeast, in the meantime the Final Results must be due in the next few days, which should make good reading. Gl ;-)

[northeast14] 24/4/2024 21:07

You just get the impression something big is brewing and could be released any day

[moneymunch] 24/4/2024 06:47

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,585 followers
18h

Safety paramount in the #biotech industry, and at Genflow Biosciences (LON:GENF) (OTCQB:GENFF), it's our top priority. We're proud to have developed patent-pending technology to enhance safety in our #SIRT6 studies.

It is this unwavering commitment to safety that has allowed us to advance a number of our studies to the pre-clinical/development stage, including treatments for diseases ranging Werner Syndrome to #NASH.

Learn more about Genflow's innovative studies & exciting investment thesis:

#GENF #aging #healthspan #NASH #genetherapy
Investors – Genflow Bioscience

[moneymunch] 23/4/2024 21:41

Cutting edge science with patents pending, compelling preclinical data progressing to human clinical trials, prestigious academic partners and a leading influential and distinguished hands on Scientific Advisory Board, at least c£4m plus cash in the bank and a market cap of £4.5m.

Exponential upside potential and prospects!!!

Will a Major Pharma/JV partner wait for positive trial results from Genflow's Nash Human Clinical Phase 1/2 trials planned for next year, or will one move early given how hot the Nash/Liver space is right now, as well as the promise of a rapidly expanding and evolving longevity market and the compelling nature of SIRT6's profound importance and influence over multiple disease targets associated with aging.

Exciting times!!! Gla holders :-)

[steg] 23/4/2024 19:30

Jigsaw coming together very nicely 👍

[northeast14] 23/4/2024 19:00

All very interesting!

[moneymunch] 23/4/2024 07:16

Acknowledgements

We thank Dr. Lin Gan from the Institutional Mouse Transgenic Core Facility at the University of Rochester for generating the Sirt6 transgenic mice.

[moneymunch] 23/4/2024 06:52

Most certainly Northeast. Gl -)



Published: 22 April 2024

Hepatic Sirt6 activation abrogates acute liver failure


Discussion

In this work, we revealed a crucial role of Sirt6 in protecting against both APAP-induced and BDL-induced ALF. Our investigation has begun from an interesting observation that hepatic Sirt6 expression significantly downregulated in the livers of human and mice with acute liver failure. The rescue and maintenance of Sirt6 expression in the Sirt6-Tg mice after APAP administration protected against the pathological changes during APAP-induced liver toxicity by limiting oxidative stress and inflammation. The protective effect of hepatic Sirt6 was further validated in Sirt6-HepTg mice and in the mice treated with the specific Sirt6 activator MDL-800. Hepatic-specific Sirt6 knockout in mice exacerbated, but hepatic overexpression of Sirt6 ameliorated, acute liver damages-induced by both APAP and BDL. Furthermore, the Sirt6 activator MDL-800 presented better therapeutic potential to alleviate liver injury in mice than NAC, which is the only proved antidote for APAP overdose up to now. Taken together, these results demonstrate that Sirt6 could be an important therapeutic target for the treatment of ALF.

..............

In conclusion, our results revealed a crucial role of hepatic Sirt6 in the protection of acute hepatotoxicity. Genetic overexpression of Sirt6 and the pharmacological activation of Sirt6 ameliorated oxidative stress, inflammation, and liver injury. The potential mechanisms whereby Sirt6 protects against hepatotoxicity include that Sirt6 inhibits JNK and caspase 3/9 activation, enhanced Nrf2/HO-1 pathway and attenuates PARP1 expression and activity. Therefore, Sirt6 orchestrates the safeguard against hepatotoxicity and may serve as a new therapeutic target for the ALF.

[northeast14] 22/4/2024 19:59

One day it will be our turn. There’s no way genflow aren’t going un noticed

[moneymunch] 22/4/2024 18:47

UK biotech signs $1bn deal to develop liver disease drugs

Ochre Bio partnering with Germany’s Boehringer Ingelheim on treatments that will harness the organ’s capacity to regenerate


Ian Johnston 14 HOURS AGO



German pharma group Boehringer Ingelheim has struck an up to $1bn partnership with a UK biotech to develop treatments for chronic liver disease that aim to harness the organ’s capacity to regenerate.

Under the drug discovery partnership, Ochre Bio will receive $35mn in upfront and near-term payments, rising to more than $1bn in payments and royalties if treatments are successfully brought through clinical trials. It is a similar milestone-based structure to many partnerships in the pharmaceutical industry.


The liver is the only organ that can regrow and repair itself and Ochre Bio will seek to develop drugs that restore this ability in diseased livers.

The company’s work to date has involved analysing thousands of donated human livers to develop an understanding of the causes of disease, and studying whether making changes to RNA — a vital molecule for translating genetic information into proteins — can extend the lifespan of transplanted livers.

“What we’re trying to do is give the liver a little nudge in the right direction to support it to regenerate,” said Quin Wills, chief scientific officer and co-founder of Ochre Bio. “What happens in a cirrhotic liver is [cells] don’t have that decision-making process any more to start dividing and restoring capacity. By changing certain ‘switches’, using these RNA therapies, we help them make those decisions again.”

There have been a series of recent developments in the treatment of liver disease, which is the third-largest cause of early death in the UK and other high-income countries. It is also the largest killer of 35- to 49-year-olds in the UK, according to the UK Health Security Agency.

The US Food and Drug Administration recently approved the first-ever drug designed specifically for the most common liver disease, metabolic dysfunction-associated steatohepatitis or mash, developed by Madrigal Pharmaceuticals.

People with mash have a build-up of fat deposits in the liver and it is estimated to affect 115mn people worldwide. The approval of Madrigal’s drug should help other treatments to pass regulatory hurdles, according to analysts at investment bank William Blair.

The disease is often linked with weight gain and has become more common as obesity levels have risen.

Pharma groups are optimistic about the potential for new weight loss and diabetes drugs known as GLP-1s to treat liver diseases.

A weight-loss drug licensed by Boehringer Ingelheim from Danish biotech Zealand Pharma has had positive results in liver disease trials, while Novo Nordisk is looking at the effect of its weight-loss drug Wegovy on mash.

But while these drugs could be used to treat early-stage disease, the industry thinks they will be less helpful against more advanced mash, which can involve extensive scarring or cirrhosis of the liver. New ways of tackling late-stage liver disease could delay the need for transplants, currently the only effective treatment.

Jack O’Meara, chief executive of Ochre Bio, told the Financial Times: “There still remains a huge unmet need there and we hope this partnership with Boehringer will be able to develop medicines that solve or offer solutions for patients at a later stage.”

Søren Tullin, head of cardiometabolic disease research at Boehringer Ingelheim, said Ochre Bio’s genomics experience and technology “holds the potential to uncover novel regenerative pathways that will make a meaningful difference in the lives of those affected by chronic liver disease”.

[moneymunch] 16/4/2024 20:56

Regeneron launches five-year $500m biotech fund

1 HOUR AGO



Biopharma giant commits $100m annually to Regeneron Ventures as it seeks to ‘fuel promising biotech innovation.’
Yesterday, as we revealed 2023 was another tough year for longevity investment, biotech heavyweight Regeneron quietly announced the formation of Regeneron Ventures, a new $500 million venture capital fund. As the fund’s exclusive limited partner, Regeneron has pledged $100 million annually over the next five years to invest in promising life sciences companies.

While the new fund’s investment mandate is broadly health focused, Regeneron Ventures says its interest is “skewed towards biotechnology, devices, tools, and enabling technologies.” The fund says that investment decisions will be guided by the quality of the science, people, and data, prioritizing “breakthrough innovation” despite the inherent risks and uncertainties. All of which should resonate well with founders in the longevity sector, offering a potential new source of funding for biotech startups targeting aging and age-related diseases.

[moneymunch] 16/4/2024 20:16

SIRT6 is an enzyme that plays an essential role in human health and contributes to epigenetic regulation of gene expression, mitochondrial health, and DNA repair. A review of literature suggests that SIRT6 could potentially help address diseases of aging, neurodegeneration, diabetes and obesity, in addition to depression. Arrivo is exploring the potential of SP-624 in multiple therapeutic areas beyond depression.

[moneymunch] 16/4/2024 19:05

Arrivo Bio Initiates Large Phase 2b Clinical Trial in Major Depressive Disorder with Novel SIRT6 Activator

Epigenetic mechanism of action offers a promising new approach to tackling MDD

April 16, 2024 08:00 AM Eastern Daylight Time
MORRISVILLE, N.C.--(BUSINESS WIRE)--

Arrivo Bio announced today a significant step forward in the fight against major depressive disorder (MDD) with the dosing of the first patient in the SP-624-202 clinical trial.

“The initiation of this study is an exciting milestone for Arrivo and the SP-624 program. Despite existing treatments, people with Major Depression often do not achieve remission and suffer unwanted side effects”


This registration-quality Phase 2b study will enroll 450 subjects with MDD and evaluate the effectiveness of SP-624, a SIRT6 activator and novel mechanism of action, compared to placebo in treating adults with Major Depressive Disorder. The SP-624-202 study will assess the change from baseline on the Montgomery-Åsberg Depression Rating Scale (MADRS) as its primary endpoint. The MADRS is a 10-item depression rating scale commonly used to assess the severity of depression in clinical trials. The large number of subjects will enable the study to explore several other investigator and patient-rated endpoints and exploratory biomarkers.

SIRT6 is an enzyme that plays an essential role in human health and contributes to epigenetic regulation of gene expression, mitochondrial health, and DNA repair. A review of literature suggests that SIRT6 could potentially help address diseases of aging, neurodegeneration, diabetes and obesity, in addition to depression. Arrivo is exploring the potential of SP-624 in multiple therapeutic areas beyond depression.

“The initiation of this study is an exciting milestone for Arrivo and the SP-624 program. Despite existing treatments, people with Major Depression often do not achieve remission and suffer unwanted side effects,” said Dr. Joel Raskin, Chief Medical Advisor at Arrivo. “This large study will significantly augment our current data on SP-624, which has the potential to be a truly transformative treatment for patients suffering from depression.”

Arrivo remains committed to advancing groundbreaking research in MDD and looks forward to sharing further developments from the SP-624-202 study. For more information on Arrivo or the SP-624-202 study, please visit www.arrivobio.com